ArticleBlood2023
The role of CD8+ T-cell clones in immune thrombocytopenia.
Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06093529 (Marker Expression in Pediatric Patients With Immune Thrombocytopenic Purpura Receiving Second Line Therapy), which is not on this map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Marker Expression in Pediatric Patients With Immune Thrombocytopenic Purpura Receiving Second Line Therapy
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Gut microbiome alterations in immune thrombocytopenia: a systematic review of current evidence.Frontiers in medicine · 2025Pooled it
- Targeting B-Cell-Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia.American journal of hematology · 2026Review
- Single-Cell Transcriptomic Profiling Identifies B Cell-Intrinsic Dysregulation of Sphingolipid Biosynthesis and Could Be Improved by Inhibiting UGCG in Primary Immune Thrombocytopenia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The association of thrombocytopenia with haematological malignancy.British journal of haematology · 2026Review
- Association and exploratory clinical significance of peripheral blood mononuclear cell microRNA-155 with T-Cell subset imbalance in newly diagnosed paediatric immune thrombocytopenia.BMC pediatrics · 2026Article
- ROCK2 inhibition suppresses cytotoxic T lymphocyte-mediated platelet destruction in primary immune thrombocytopenia.Cell & bioscience · 2026Article
- Human GPR174 deficiency drives polyclonal lymphoproliferative disease via defects in T cell function.medRxiv : the preprint server for health sciences · 2026Article
- Article
- A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.British journal of haematology · 2026Article
- Single-Cell Analysis Highlights Pivotal Role of Eosinophil-Basophil Mast Cell Progenitor-Related Mechanism in Primary Immune Thrombocytopenia.International journal of molecular sciences · 2026Article
- Platelet desialylation, apoptosis, and T-lymphocyte-mediated immune dysregulation: unveiling the pathways of platelet clearance in platelet transfusion refractoriness.Research and practice in thrombosis and haemostasis · 2026Article
- Characterizing mouse platelet heterogeneity across diverse disease models using spectral flow cytometry and high-dimensional analysis.Research and practice in thrombosis and haemostasis · 2026Article
- Inflammatory cytokines, inflammasomes, and neutrophil extracellular traps in primary immune thrombocytopenia pathogenesis.Blood vessels, thrombosis & hemostasis · 2026Review
- Genetically Predicted 12,13-DiHOME Mediates the Association between TNF-Related Apoptosis-Inducing Ligand and Immune Thrombocytopenia.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Clinical characteristics and decreased CD4Frontiers in immunology · 2026Article
- Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients.Frontiers in oncology · 2026Article
- Beyond HLA: an exploratory pilot study of non-HLA antibodies, HLA sensitization, and GSTT1 genotype in platelet transfusion refractoriness.Frontiers in immunology · 2026Article
- MPL receptor dimerization and the thrombopoietin pathway in primary immune thrombocytopenia: from molecular mechanisms to targeted therapies.Frontiers in medicine · 2026Review
- Correlation between the CD8Frontiers in pediatrics · 2026Article
- Refractory ITP: revisiting definitions, diagnostics, and management paradigms.Hematology. American Society of Hematology. Education Program · 2025Review
Corrections and comments
- Commented on by
Authors and funding
23 authors at 10 institutions in 4 countries.
Funding
Abstract
Immune thrombocytopenia (ITP) is traditionally considered an antibody-mediated disease. However, a number of features suggest alternative mechanisms of platelet destruction. In this study, we use a multidimensional approach to explore the role of cytotoxic CD8+ T cells in ITP. We characterized patients with ITP and compared them with age-matched controls using immunophenotyping, next-generation sequencing of T-cell receptor (TCR) genes, single-cell RNA sequencing, and functional T-cell and platelet assays. We found that adults with chronic ITP have increased polyfunctional, terminally differentiated effector memory CD8+ T cells (CD45RA+CD62L-) expressing intracellular interferon gamma, tumor necrosis factor α, and granzyme B, defining them as TEMRA cells. These TEMRA cells expand when the platelet count falls and show no evidence of physiological exhaustion. Deep sequencing of the TCR showed expanded T-cell clones in patients with ITP. T-cell clones persisted over many years, were more prominent in patients with refractory disease, and expanded when the platelet count was low. Combined single-cell RNA and TCR sequencing of CD8+ T cells confirmed that the expanded clones are TEMRA cells. Using in vitro model systems, we show that CD8+ T cells from patients with ITP form aggregates with autologous platelets, release interferon gamma, and trigger platelet activation and apoptosis via the TCR-mediated release of cytotoxic granules. These findings of clonally expanded CD8+ T cells causing platelet activation and apoptosis provide an antibody-independent mechanism of platelet destruction, indicating that targeting specific T-cell clones could be a novel therapeutic approach for patients with refractory ITP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.